Disease · MONDO_0001942

generalized anxiety disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. generalized anxiety disorder. Diseases, record MONDO_0001942. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001942

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: generalized anxiety disorder; Open Targets
Open Targets ID: MONDO_0001942; Open Targets
Other names: GAD, generalised anxiety disorder, generalised anxiety disorders, generalized anxiety disorders; Open Targets
Disease Ontology: DOID:14320; Disease Ontology
NCI Thesaurus: C92622; NCI Thesaurus
Highest stage of its drugs: Approval, for 4 of its 59 drugs, from ClinicalTrials.gov and DailyMed; Open Targets

Drugs59

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
DULOXETINE HYDROCHLORIDE	CHEMBL1200328	Small molecule	Approval	ClinicalTrials.gov	2	2	2	Drugs and targets
ALPRAZOLAM	CHEMBL661	Small molecule	Approval	DailyMed	6	1	1	Drugs and targets
ESCITALOPRAM OXALATE	CHEMBL1200322	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
BUSPIRONE HYDROCHLORIDE	CHEMBL1200399	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
ESCITALOPRAM	CHEMBL1508	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
DULOXETINE	CHEMBL1175	Small molecule	Phase 3	ClinicalTrials.gov	9	9	9	Drugs and targets
IMAGABALIN	CHEMBL2103836	Small molecule	Phase 3	ClinicalTrials.gov and TTD	9	8	8	Drugs and targets
PAROXETINE	CHEMBL490	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
QUETIAPINE FUMARATE	CHEMBL3188993	Small molecule	Phase 3	ClinicalTrials.gov	7	7	7	Drugs and targets
VENLAFAXINE	CHEMBL637	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets

1 to 10 of 59

See all 59 drugs

Targets91

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A4	Sodium-dependent serotonin transporter	15	Serotonin transporter inhibitor	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
SLC6A2	Sodium-dependent noradrenaline transporter	7	Norepinephrine transporter inhibitor	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
GABRA1	GABA A receptor alpha-1/beta-1/gamma-2	6	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2554	Drugs and targets
GABRB1	GABA A receptor alpha-1/beta-1/gamma-2	6	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2560	Drugs and targets
GABRG2	GABA A receptor alpha-1/beta-1/gamma-2	6	GABA A receptor alpha-1/beta-1/gamma-2 positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2566	Drugs and targets
HTR1A	5-hydroxytryptamine receptor 1A	6	Serotonin 1a (5-HT1a) receptor agonist; Serotonin 1a (5-HT1a) receptor partial agonist	Approval	https://conductscience.org/library/genes/3350	Drugs and targets
GABRA2	GABA-A receptor; anion channel	5	GABA receptor alpha-2 subunit positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	5	GABA receptor alpha-3 subunit positive allosteric modulator; GABA-A receptor; anion channel agonist; GABA-A receptor; anion channel positive allosteric modulator	Approval	https://conductscience.org/library/genes/2556	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	5	Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
DRD2	D(2) dopamine receptor	4	Dopamine D2 receptor antagonist; Dopamine D2 receptor modulator	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets

1 to 10 of 91

See all 91 targets

Trials107

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03829241	Randomized Trial of Adult Participants With Generalized Anxiety Disorder	Phase 3	881	2022-12-28	Generalized Anxiety Disorder	TRORILUZOLE	Its record names the disease	ClinicalTrials.gov
NCT00730691	Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder	Phase 3	781	2013-12-18	Generalized Anxiety Disorder	DULOXETINE, VORTIOXETINE	Its record names the disease	ClinicalTrials.gov
NCT00808249	AZD7325 Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)	Phase 2	725	2011-05-19	Anxiety Disorders	AZD7325	Its record names the disease	ClinicalTrials.gov
NCT01629966	Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder	Phase 3	680	2019-12-18	Generalized Anxiety Disorder	VILAZODONE	Its record names the disease	ClinicalTrials.gov
NCT02305797	EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)	Phase 3	495	2018-09-26	Generalized Anxiety Disorder (GAD)	LORAZEPAM	Its record names the disease	ClinicalTrials.gov
NCT00052078	Child and Adolescent Anxiety Disorders (CAMS)	Phase 3	488	2017-04-25	Anxiety Disorders, Social Phobia, Generalized Anxiety Disorder	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT00731120	Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder	Phase 3	457	2013-12-18	Generalized Anxiety Disorder	VORTIOXETINE	Its record names the disease	ClinicalTrials.gov
NCT00616655	Generalized Anxiety Disorder Proof of Concept Efficacy and Safety Study of SEP-225441 (Eszopiclone) In GAD Subjects	Phase 2	456	2015-08-21	Generalized Anxiety Disorder	ESZOPICLONE	Its record names the disease	ClinicalTrials.gov
NCT00389064	Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder	Phase 3	450	2009-06-23	Anxiety Disorders	QUETIAPINE FUMARATE	Its record names the disease	ClinicalTrials.gov
NCT01844115	Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder	Phase 3	415	2019-12-18	Generalized Anxiety Disorder	VILAZODONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 107

See all 107 trials

Comparisons in its trials33

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
EDG004 vs Placebo: serious adverse events	2 of 247	0 of 248	495	NCT02305797	Trial comparisons
Quetiapine XR vs Placebo: Safety and Well Tolerated as Measured in Adverse Event	145 of 223	114 of 227	450	NCT00389064	Trial comparisons
Quetiapine XR vs Placebo: serious adverse events	1 of 223	3 of 227	450	NCT00389064	Trial comparisons
Quetiapine XR vs Placebo: serious adverse events	0 of 209	0 of 200	409	NCT00534599	Trial comparisons
Vilazodone vs Placebo: deaths from any cause	0 of 202	0 of 202	404	NCT01844115	Trial comparisons
Vilazodone vs Placebo: serious adverse events	3 of 202	0 of 202	404	NCT01844115	Trial comparisons
Quetiapine XR vs Placebo: Number of Patients With HAM-A Remission (Total Score ≤7) at Week 8	48 of 204	34 of 198	402	NCT00534599	Trial comparisons
Quetiapine XR vs Placebo: Number of Patients With HAM-A Response (≥50% Score Reduction From Randomization) at Week 8	84 of 204	72 of 198	402	NCT00534599	Trial comparisons
Quetiapine XR vs Placebo: Number of Patients With Clinical Global Impression-Global Improvement (CGI-I) Score of Much/Very Much Improved at Week 8	114 of 204	97 of 198	402	NCT00534599	Trial comparisons
Vilazadone vs Placebo: deaths from any cause	0 of 200	0 of 198	398	NCT01766401	Trial comparisons

1 to 10 of 33

See all 33 comparisons in its trials

Papers from its trials101

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
32857933	RESULT	1	PubMed
32721213	RESULT	1	PubMed
29710504	RESULT	1	PubMed
29017144	RESULT	1	PubMed
28384010	RESULT	1	PubMed
25721183	RESULT	2	PubMed
25486372	RESULT	1	PubMed
24625685	RESULT	1	PubMed
24565357	RESULT	2	PubMed
24417601	RESULT	1	PubMed

1 to 10 of 101

See all 101 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001942

GET https://conductscience.org/api/diseases/v1/MONDO_0001942/drugs?page=2

API reference For AI assistants